# US 2021/0275641 A1 · Biased il2 muteins methods and compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275641 A1
- Document ID: US20210275641A1
- Status: Published application
- Kind: A1
- Application number: 17/149,405
- Filed: 2021-01-14
- Published: 2021-09-09
- Earliest claimed: 2020-01-14
- Assignees: Synthekine, Inc.
- Applicants: Synthekine, Inc.
- Inventors: Jan Emmerich; Steve Kauder; Scott Alan McCauley; Martin Oft
- Web page: https://patentgrep.com/patent/US20210275641A1

## CPC

- A61K 38/2013: {IL-2}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 35/76: Viruses; Subviral particles; Bacteriophages
- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- C07K 14/55: IL-2
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The present disclosures related to human interleukin-2 (hIL2) muteins, pharmaceutical formulations thereof, methods for preparing interleukin-2 muteins, recombinant vectors and cells comprising nucleic acids encoding IL2 muteins and methods for the treatment of human disease.

## Claims

### Claim 1

A method of treating a subject suffering from a neoplastic disease, disorder or condition, the method comprising administrating to said subject a polypeptide that is at least 95% homologous to a polypeptide of the formula: 1:
(AA1)a-(AA2)b-(AA3)c-(AA4)d-(AA5)e-(AA6)f-
(AA7)g-(AA8)h-(AA9)i-T10-Q11-L12-Q13-L14-E15-
H16-L17-(AA18)-L19-D20-L21-(AA22)-M23-I24-L25-
N26-G27-I28-N29-N30-Y31-K32-N33-P34-(AA35)-L36-
T37-(AA38)-(AA39)-L40-T41-F42-K43-F44-Y45-M46-
P47-K48-K49-A50-T51-E52-L53-K54-(AA55)-L56-Q57-
C58-L59-E60-E61-E62-L63-K64-P65-L66-E67-E68-
(AA69)-L70-N71-L72-A73-(AA74)-S75-K76-N77-F78-
H79-(AA80-(AA81)-P82-R83-D84-(AA85)-(AA86)-S87-
N88-(AA89)-N90-(AA91)-(AA92)-V93-L94-E95-L96-
(AA97)-G98-S99-E100-T101-T102-F103-(AA104)-C105-
E106-Y107-A108-(AA109)-E110-T111-A112-(AA113)-
I114-V115-E116-F117-L118-N119-R120-W121-I122-
T123-F124-(AA125)-(AA126)-S127-I128-I129-
(AA130)-T131-L132-T133
wherein:
each of a, b, c, d, e, f, g, h, and i is individually selected from 0 or 1;
AA1 is A (wild type, a=1) or deleted (a=0);
AA2 is P (wild type, b=1) or deleted (b=0);
AA3 is T (wild type, c=1), C, A, G, Q, E, N, D, R, K, P, or deleted (c=0);
AA4 is S (wild type, d=1) or deleted (d=0);
AA5 is S (wild type, e=1) or deleted (e=0);
AA6 is S (wild type, f=1) or deleted (f=0);
AA7 is T (wild type, g=1) or deleted (g=0);
AA8 is K (wild type, h=1) or deleted (h=0);
AA9 is K (wild type, i=1) or deleted (i=0);
AA18 is L (wild type) or R, L, G, M, F, E, H, W, K, Q, S, V, I, Y, H, D or T;
AA22 is Q (wild type) or F, E, G, A, L, M, F, W, K, S, V, I, Y, H, R, N, D, T, or F;
AA35 is K (wildtype) or E;
AA38 is R (wild type), W or G;
AA39 is M (wildtype), L or V;
AA55 is H (wildtype) or Y;
AA69 is V (wildtype) or A;
AA74 is Q (wild type), P, N, H, S;
AA80 is L (wild type), F or V;
AA81 is R (wild type), I, D or T;
AA85 is L (wild type) or V;
AA86 is I (wild type) or V;
AA89 is I (wild type) or V;
AA91 is V (wild type), R, or K;
AA92 is I (wild type) or F;
AA97 is K (wild type) or Q;
AA104 is M (wild type) or A;
AA109 is D (wildtype), C or a non-natural amino acid with an activated side chain;
AA113 is T (wild type) or N;
AA125 is C (wild type), A or S;
AA126 is Q (wild type) or H, M, K, C, D, E, G, I, R, S, or T; and
AA130 is S (wild type), T, G or R.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The method of claim 1 wherein the polypeptide comprises the following mutations:
a=0;
AA18 is selected from the group consisting of L (wild type) or R, L, G, M, F, E, H, W, K, Q, S, V, I, Y, H, D or T;
AA22 is selected from the group consisting of Q (wild type) or F, E, G, A, L, M, F, W, K, S, V, I, Y, H, R, N, D, T, or F; and
AA126 is selected from the group consisting of Q (wild type) or H, M, K, C, D, E, G, I, R, S, or T.

### Claim 4 (depends on 1)

The method of claim 1 wherein the polypeptide comprises a set of mutations selected from the following sets of mutations: L18R, Q22E, and Q126H; L18R, Q22E, and Q126K; L18R, Q22E and Q126M; L18R, Q22E Q126T; L18R; Q22E; V91K; V91R; Q126H; L18R, and Q126H; Q22E, and Q126H; L18G, Q22E and Q126H; L18A, Q22E and Q126H; L18M, Q22E and Q126H; L18F, Q22E and Q126H; L18W, Q22E and Q126H; L18K, Q22E and Q126H; L18Q, Q22E and Q126H; L18E, Q22E and Q126H; L18S, Q22E and Q126H; L18V, Q22E and Q126H; L18I, Q22E and Q126H; L18Y, Q22E and Q126H; L18H, Q22E and Q126H; L18N, Q22E and Q126H; L18D, Q22E and Q126H; L18T, Q22E and Q126H; L18R, Q22G and Q126H; L18R, Q22A and Q126H; L18R, Q22L and Q126H; L18R, Q22M and Q126H; L18R, Q22F and Q126H; L18R, Q22W and Q126H; L18R, Q22K and Q126H; L18R, Q22S and Q126H; L18R, Q22V and Q126H; L18R, Q22I and Q126H; L18R Q22Y and Q126H; L18R Q22H and Q126H; L18R Q22R and Q126H; L18R Q22N and Q126H; L18R Q22D and Q126H; and L18R Q22T and Q126H.

### Claim 5 (depends on 1)

The method of claim 1, wherein the polypeptide is PEGylated.

### Claim 6

(canceled)

### Claim 7 (depends on 5)

The method of claim 5, wherein the polypeptide is PEGylated with a PEG having a molecular weight of from about 40 kD.

### Claim at position 8

8-9. (canceled)

### Claim 10 (depends on 1)

The method of claim 1, wherein the administering comprises administering a nucleic acid encoding the polypeptide.

### Claim 11 (depends on 10)

The method of claim 10, wherein the nucleic acid is DNA.

### Claim 12 (depends on 10)

The method of claim 10, wherein the nucleic acid is a recombinant expression vector.

### Claim 13 (depends on 12)

The method of claim 12, wherein said vector is a viral vector.

### Claim 14 (depends on 12)

The method of claim 12 wherein said vector is a non-viral vector.

### Claim at position 14

15-17. (canceled)

### Claim 18 (depends on 1)

The method of claim 1, wherein said method further comprises administering a supplementary agent to said subject.

### Claim 19 (depends on 18)

The method of claim 18 wherein said supplementary agent is selected from the group consisting of chemotherapeutic agents, antibodies, immune checkpoint modulators, tumor infiltrating lymphocytes (TILS), CAR-T cells, and physical methods.

### Claim 20 (depends on 19)

The method of claim 19 wherein the supplementary agent is an immune checkpoint modulator.

### Claim 21 (depends on 20)

The method of claim 20 wherein the immune checkpoint modulator is an anti-PD-1 antibody or an anti-PD-L1 antibody.

### Claim at position 19

22-24. (canceled)

### Claim 25 (depends on 1)

The method of claim 1, wherein the polypeptide comprises SEQ ID NO:8.

### Claim 26 (depends on 25)

The method of claim 25, wherein the polypeptide comprises an amino-terminal proline that is linked to a peglyated linker comprising:

### Claim 27 (depends on 21)

The method of claim 21, wherein the anti-PD-1 antibody is nivolumab or pembrolizumab.
